Neoadjuvant radioimmunotherapy synergy in triple-negative breast cancer: Is microenvironment-guided patient selection on the horizon?

Simona F Shaitelman; Wendy A Woodward

doi:10.1016/j.ccell.2023.12.009

Neoadjuvant radioimmunotherapy synergy in triple-negative breast cancer: Is microenvironment-guided patient selection on the horizon?

Cancer Cell. 2024 Jan 8;42(1):10-12. doi: 10.1016/j.ccell.2023.12.009.

Authors

Simona F Shaitelman¹, Wendy A Woodward²

Affiliations

¹ Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
² Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. Electronic address: wwoodward@mdanderson.org.

PMID: 38194911
DOI: 10.1016/j.ccell.2023.12.009

Abstract

Neoadjuvant chemotherapy plus immunotherapy for triple-negative breast cancer (TNBC) is associated with improved but incomplete response. In this issue of Cancer Cell, Shiao et al. characterize longitudinal biopsies from a window of opportunity study with single-cell RNA sequencing (scRNA-seq) and spatial proteomic profiling and elucidate synergy between radiotherapy (RT) and pembrolizumab.

Publication types

Comment

MeSH terms

Humans
Neoadjuvant Therapy
Patient Selection
Proteomics
Radioimmunotherapy*
Triple Negative Breast Neoplasms* / genetics
Triple Negative Breast Neoplasms* / radiotherapy
Tumor Microenvironment